评估前列腺癌遗传风险对基层医疗中PSA检测使用的影响:一项整群随机对照试验
该整群随机对照试验在丹麦中部地区73对全科诊所开展,干预组男性在标准PSA检测外接受基于33个风险相关SNP的遗传检测以获知前列腺癌终生遗传风险。结果显示提供遗传检测未减少未来PSA检测总数,但在接受遗传检测的男性中,高遗传风险者2年内重复PSA检测的倾向显著高于正常风险者(OR=8.94,p<0.01)。
要点
- 向全科医生提供前列腺癌终生遗传风险检测未减少总体未来PSA检测数量。
- 在接受遗传检测的男性中,高遗传风险者2年内重复PSA检测的倾向显著高于正常风险者(OR=8.94,p<0.01)。
- 研究在常规实践中开展,存在选择偏倚,接受遗传检测者中年轻和高收入参与者比例较大。
核心结论
- 提供全科医生获取前列腺癌终生遗传风险检测未减少未来PSA检测的总体数量。
- 在接受遗传检测的男性中,知晓遗传风险显著影响未来PSA检测行为。
研究设计与样本
- 整群随机对照试验,在丹麦中部地区全科诊所层面随机分组,每组73家诊所。
- 干预组男性在标准PSA检测外接受基于33个风险相关单核苷酸多态性(SNP)的遗传检测,区分「正常」与「高」风险。
- 排除标准应用后,干预组招募3,558名男性,其中1,235名(34.7%)接受遗传检测;对照组招募4,242名男性。
- 主要结局为2年内重复PSA检测的男性比例,采用多水平logistic回归模型检验关联。
主要发现
- 高遗传风险男性2年内重复PSA检测的倾向高于正常遗传风险男性(OR=8.94,p<0.01)。
- 提供遗传检测未减少未来PSA检测的总体数量。
关键数值与推荐
- 遗传检测基于33个风险相关SNP的基因分型,区分「正常」与「高」终生遗传风险。
- 主要结局为2年内重复PSA检测的比例。
- 高遗传风险者2年内重复PSA检测的OR=8.94,p<0.01。
临床怎么用
- 在全科实践中引入前列腺癌遗传风险检测不应期望减少总体PSA检测数量。
- 遗传风险信息可能影响已接受检测男性的后续PSA检测行为,高遗传风险者更倾向于重复检测。
局限性
- 研究在常规实践中开展,存在选择偏倚。
- 接受遗传检测者中年轻和高收入参与者比例较大,提示选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Assessing genetic lifetime risk for prostate cancer has been proposed as a means of risk stratification to identify those for whom prostate-specific antigen (PSA) testing is likely to be most valuable. This project aimed to test the effect of introducing a genetic test for lifetime risk of prostate cancer in general practice on future PSA testing. METHODS AND FINDINGS: We performed a cluster randomized controlled trial with randomization at the level of general practices (73 in each of two arms) in the Central Region (Region Midtjylland) of Denmark. In intervention practices, men were offered a genetic test (based on genotyping of 33 risk-associated single nucleotide polymorphisms) in addition to the standard PSA test that informed them about lifetime genetic risk of prostate cancer and distinguished between "normal" and "high" risk. The primary outcome was the proportion of men having a repeated PSA test within 2 years. A multilevel logistic regression model was used to test the association. After applying the exclusion criteria, 3,558 men were recruited in intervention practices, with 1,235 (34.7%) receiving the genetic test, and 4,242 men were recruited in control practices. Men with high genetic risk had a higher propensity for repeated PSA testing within 2 years than men with normal genetic risk (odds ratio [OR] = 8.94, p < 0.01). The study was conducted in routine practice and had some selection bias, which is evidenced by the relatively large proportion of younger and higher income participants taking the genetic test. CONCLUSIONS: Providing general practitioners (GPs) with access to a genetic test to assess lifetime risk of prostate cancer did not reduce the overall number of future PSA tests. However, among men who had a genetic test, knowledge of genetic risk significantly influenced future PSA testing. TRIAL REGISTRATION: This study is registered with ClinicalTrials.gov, number NCT01739062.
引用
- Fredsøe J, Koetsenruyter J, Vedsted P, et al. The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial. PLoS Med. 2020. PMID: 32032355. doi:10.1371/journal.pmed.1003033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。